JP2019518071A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518071A5 JP2019518071A5 JP2019505347A JP2019505347A JP2019518071A5 JP 2019518071 A5 JP2019518071 A5 JP 2019518071A5 JP 2019505347 A JP2019505347 A JP 2019505347A JP 2019505347 A JP2019505347 A JP 2019505347A JP 2019518071 A5 JP2019518071 A5 JP 2019518071A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- ring
- alkoxy
- hydroxy
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 285
- 125000000217 alkyl group Chemical group 0.000 claims description 265
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 220
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 181
- 239000001257 hydrogen Substances 0.000 claims description 170
- 150000002431 hydrogen Chemical class 0.000 claims description 128
- 229910052799 carbon Inorganic materials 0.000 claims description 106
- 125000005843 halogen group Chemical group 0.000 claims description 105
- 125000003545 alkoxy group Chemical group 0.000 claims description 91
- 150000001875 compounds Chemical class 0.000 claims description 86
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 81
- 229910052801 chlorine Inorganic materials 0.000 claims description 70
- 125000004429 atom Chemical group 0.000 claims description 68
- 229910052757 nitrogen Inorganic materials 0.000 claims description 54
- 125000001424 substituent group Chemical group 0.000 claims description 54
- 229910052760 oxygen Inorganic materials 0.000 claims description 50
- 229920006395 saturated elastomer Polymers 0.000 claims description 48
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 42
- 125000000623 heterocyclic group Chemical group 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 30
- 125000005842 heteroatom Chemical group 0.000 claims description 28
- 229910052717 sulfur Inorganic materials 0.000 claims description 28
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 26
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims description 25
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 53
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 35
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 25
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 13
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 11
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 8
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 description 63
- 238000000034 method Methods 0.000 description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 20
- 201000010099 disease Diseases 0.000 description 18
- 208000035475 disorder Diseases 0.000 description 18
- 125000004438 haloalkoxy group Chemical group 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 0 CCC*CCC1CC(CCCCC2C*CC2)C1 Chemical compound CCC*CCC1CC(CCCCC2C*CC2)C1 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- -1 1-hydroxycyclopropyl Chemical group 0.000 description 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 description 2
- 208000016222 Pancreatic disease Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- AZQNAXVWWGNZRQ-UHFFFAOYSA-N CC(C)C1N(C)C1 Chemical compound CC(C)C1N(C)C1 AZQNAXVWWGNZRQ-UHFFFAOYSA-N 0.000 description 1
- DSPQPTFYGZZJKM-UHFFFAOYSA-N CCC1C(C)C(C)(CC)CC(C)(C)C1 Chemical compound CCC1C(C)C(C)(CC)CC(C)(C)C1 DSPQPTFYGZZJKM-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324081P | 2016-04-18 | 2016-04-18 | |
| US201662324071P | 2016-04-18 | 2016-04-18 | |
| US62/324,071 | 2016-04-18 | ||
| US62/324,081 | 2016-04-18 | ||
| PCT/US2017/028167 WO2017184624A1 (en) | 2016-04-18 | 2017-04-18 | Compounds and compositions for treating conditions associated with nlrp activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019518071A JP2019518071A (ja) | 2019-06-27 |
| JP2019518071A5 true JP2019518071A5 (OSRAM) | 2020-05-28 |
Family
ID=58664792
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505346A Expired - Fee Related JP7050751B2 (ja) | 2016-04-18 | 2017-04-18 | Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物 |
| JP2019505347A Ceased JP2019518071A (ja) | 2016-04-18 | 2017-04-18 | Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505346A Expired - Fee Related JP7050751B2 (ja) | 2016-04-18 | 2017-04-18 | Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11339136B2 (OSRAM) |
| EP (3) | EP3445757B1 (OSRAM) |
| JP (2) | JP7050751B2 (OSRAM) |
| AU (2) | AU2017254522B2 (OSRAM) |
| ES (2) | ES2855732T3 (OSRAM) |
| MA (2) | MA56008A (OSRAM) |
| WO (2) | WO2017184624A1 (OSRAM) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3046933B1 (fr) * | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| JP7050751B2 (ja) | 2016-04-18 | 2022-04-08 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物 |
| MA55695A (fr) | 2017-01-23 | 2022-02-23 | Genentech Inc | Composés chimiques comme inhibiteurs de l'activité interleukine-1 |
| CA3059458A1 (en) | 2017-05-24 | 2018-11-29 | The University Of Queensland | Novel compounds and uses |
| DK3661925T3 (da) | 2017-07-07 | 2022-02-28 | Inflazome Ltd | Hidtil ukendte sulfonamidcarboxamidforbindelser |
| US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| WO2019023145A1 (en) * | 2017-07-24 | 2019-01-31 | IFM Tre, Inc. | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY |
| HRP20240521T1 (hr) | 2017-07-24 | 2024-07-05 | Novartis Ag | Spojevi i pripravci za liječenje stanja povezanih s aktivnošću nlrp |
| TW201910317A (zh) * | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| US12221434B2 (en) | 2017-11-09 | 2025-02-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| MA50567A (fr) | 2017-11-09 | 2020-09-16 | Inflazome Ltd | Nouveaux composés de sulfonamide carboxamide |
| EP3759073A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Sulfonamide derivates as nlrp3 inhibitors |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2019166627A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| KR20210016344A (ko) | 2018-05-04 | 2021-02-15 | 인플라좀 리미티드 | 신규한 화합물 |
| EP3817815A1 (en) * | 2018-07-03 | 2021-05-12 | Novartis AG | Nlrp modulators |
| CA3103664A1 (en) | 2018-07-03 | 2020-01-09 | Novartis Ag | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist |
| EP3817817A1 (en) * | 2018-07-03 | 2021-05-12 | Novartis AG | Nlrp modulators |
| EP3823726A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche SA | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| UA128558C2 (uk) | 2018-07-20 | 2024-08-14 | Ф. Хоффманн-Ля Рош Аг | Сульфонімідамідні сполуки як інгібітори активності інтерлейкіну-1 |
| BR112021002770A2 (pt) | 2018-08-15 | 2021-05-04 | Inflazome Limited | compostos inovadores de sulfonamidaurea |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| EP3870565A1 (en) * | 2018-10-24 | 2021-09-01 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| WO2020102098A1 (en) * | 2018-11-13 | 2020-05-22 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| PH12021500025A1 (en) * | 2018-11-13 | 2022-05-02 | Novartis Ag | Compound and compositions for treating conditions associated with nlrp activity |
| WO2020102100A1 (en) | 2018-11-13 | 2020-05-22 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| JP2022507505A (ja) * | 2018-11-16 | 2022-01-18 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| GB201819083D0 (en) * | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| MY209594A (en) | 2019-01-14 | 2025-07-23 | Zydus Lifesciences Ltd | Novel substituted sulfonylurea derivatives |
| GB201905265D0 (en) | 2019-04-12 | 2019-05-29 | Inflazome Ltd | Inflammasome inhibition |
| CN111848461A (zh) * | 2019-04-29 | 2020-10-30 | 苏州大学 | Nlrp3炎症小体抑制剂及其制备方法和应用 |
| AU2020296829A1 (en) * | 2019-06-17 | 2022-02-10 | Olatec Therapeutics Llc | Method for treating asthma |
| WO2020254697A1 (en) | 2019-06-21 | 2020-12-24 | Ac Immune Sa | Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators |
| WO2021002887A1 (en) * | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| CA3151865A1 (en) * | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as nlpr3 modulators for the treatment of multiple sclerosis (ms) |
| AU2020314186A1 (en) | 2019-07-17 | 2022-02-24 | Zomagen Biosciences Ltd | NLRP3 modulators |
| JP2022545400A (ja) | 2019-08-16 | 2022-10-27 | インフレイゾーム リミテッド | Ｎｌｒｐ３阻害剤として有用な大環状スルホニル尿素誘導体 |
| WO2021043966A1 (en) | 2019-09-06 | 2021-03-11 | Inflazome Limited | Nlrp3 inhibitors |
| CN111100042B (zh) * | 2019-11-18 | 2022-05-31 | 苏州诚和医药化学有限公司 | 一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法 |
| CN111018750B (zh) * | 2019-12-19 | 2022-05-27 | 苏州诚和医药化学有限公司 | 一种2,3-二甲氧基-5-磺酰胺基苯甲酸的制备新方法 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| CN115362152A (zh) | 2020-02-18 | 2022-11-18 | 英夫拉索姆有限公司 | 化合物 |
| PH12022552447A1 (en) * | 2020-03-16 | 2024-01-03 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| EP4121032A1 (en) | 2020-03-19 | 2023-01-25 | Softhale NV | Method for the treatment nlrp3-associated diseases |
| CN115768749B (zh) * | 2020-06-11 | 2024-04-19 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物 |
| KR20230028425A (ko) | 2020-06-19 | 2023-02-28 | 에이씨 이뮨 에스에이 | Nlrp3 인플라마좀 경로를 조절하는 디하이드로옥사졸 및 티오우레아 또는 우레아 유도체 |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
| CN117279903A (zh) * | 2021-02-10 | 2023-12-22 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| WO2022237780A1 (zh) * | 2021-05-10 | 2022-11-17 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| CN118355000A (zh) * | 2021-12-03 | 2024-07-16 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物的盐型及晶型 |
| US20250109126A1 (en) | 2021-12-22 | 2025-04-03 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
| WO2024013395A1 (en) | 2022-07-14 | 2024-01-18 | Ac Immune Sa | Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway |
| IL318406A (en) | 2022-07-28 | 2025-03-01 | Ac Immune Sa | New compounds |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| WO2024249539A1 (en) | 2023-06-02 | 2024-12-05 | Merck Sharp & Dohme Llc | 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3 |
| WO2025133307A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153625A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153624A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL98784A0 (en) * | 1990-07-17 | 1992-07-15 | Lilly Co Eli | Heterocyclyl sulfonamide derivatives,process for their preparation and pharmaceutical compositions containing them |
| US5169860A (en) | 1992-03-13 | 1992-12-08 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| CA2110524A1 (en) | 1992-12-10 | 1994-06-11 | Gerald Burr Grindey | Antitumor compositions and methods of treatment |
| EP0964849B1 (en) * | 1997-01-29 | 2003-06-04 | Pfizer Inc. | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| EP0987552A3 (en) * | 1998-08-31 | 2000-06-07 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
| BR0014003A (pt) | 1999-09-14 | 2002-05-21 | Pfizer Prod Inc | Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra |
| CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| CA2468706A1 (en) * | 2001-11-30 | 2003-06-05 | Mark Anthony Dombroski | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| DK200600313A (da) * | 2006-03-03 | 2006-03-13 | Novo Nordisk As | Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor |
| CA2913154A1 (en) | 2013-05-21 | 2014-11-27 | Virginia Commonwealth University | Cryopyrin inhibitors for preventing and treating inflammation |
| IL253661B2 (en) | 2015-02-16 | 2024-01-01 | Univ Queensland | Sulfonylureas bearing a five-membered ring, and pharmaceutical compositions and uses thereof |
| JP7050751B2 (ja) | 2016-04-18 | 2022-04-08 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物 |
-
2017
- 2017-04-18 JP JP2019505346A patent/JP7050751B2/ja not_active Expired - Fee Related
- 2017-04-18 WO PCT/US2017/028167 patent/WO2017184624A1/en not_active Ceased
- 2017-04-18 EP EP17720928.5A patent/EP3445757B1/en active Active
- 2017-04-18 MA MA056008A patent/MA56008A/fr unknown
- 2017-04-18 EP EP20208882.9A patent/EP3872070A1/en not_active Withdrawn
- 2017-04-18 US US16/094,499 patent/US11339136B2/en active Active
- 2017-04-18 ES ES17720928T patent/ES2855732T3/es active Active
- 2017-04-18 AU AU2017254522A patent/AU2017254522B2/en not_active Ceased
- 2017-04-18 ES ES17722216T patent/ES2927777T3/es active Active
- 2017-04-18 MA MA044729A patent/MA44729A/fr unknown
- 2017-04-18 WO PCT/US2017/028166 patent/WO2017184623A1/en not_active Ceased
- 2017-04-18 AU AU2017254523A patent/AU2017254523B2/en not_active Ceased
- 2017-04-18 EP EP17722216.3A patent/EP3445756B1/en active Active
- 2017-04-18 JP JP2019505347A patent/JP2019518071A/ja not_active Ceased
- 2017-04-18 US US16/094,491 patent/US11597706B2/en active Active
-
2022
- 2022-04-01 US US17/711,205 patent/US11760735B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518071A5 (OSRAM) | ||
| JP2019519598A5 (OSRAM) | ||
| JP2019515952A5 (OSRAM) | ||
| JP2020537657A5 (OSRAM) | ||
| JP2020528889A5 (OSRAM) | ||
| HRP20251344T1 (hr) | SPOJEVI I PRIPRAVCI ZA LIJEČENJE STANJA POVEZANIH S AKTIVNOŠĆU NLRP-a | |
| HRP20240521T1 (hr) | Spojevi i pripravci za liječenje stanja povezanih s aktivnošću nlrp | |
| JP2014037426A5 (OSRAM) | ||
| RU2014110623A (ru) | Пирролопиразиновые ингибиторы киназы | |
| JP2019518766A5 (OSRAM) | ||
| JP2017510642A5 (OSRAM) | ||
| JPWO2020102096A5 (OSRAM) | ||
| JP2020521741A5 (OSRAM) | ||
| JP2013510825A5 (OSRAM) | ||
| JP2019516713A5 (OSRAM) | ||
| JP2017510644A5 (OSRAM) | ||
| JP2018070614A5 (OSRAM) | ||
| JP2012532112A5 (OSRAM) | ||
| HRP20240414T1 (hr) | Supstituirani indazoli, postupak za njihovu pripremu, farmaceutske formulacije koje ih sadrže i njihova upotreba za pripremu lijekova | |
| JP2017510643A5 (OSRAM) | ||
| RU2018105549A (ru) | Производные бензодиазепина как ингибиторы rsv | |
| JP2019524883A5 (OSRAM) | ||
| JP2015528812A5 (OSRAM) | ||
| JP2019522055A5 (OSRAM) | ||
| JPWO2019213526A5 (OSRAM) |